Could a diabetes drug make heart inflammation easier to spot?

NCT ID NCT06510894

Recruiting now Diagnosis Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a drug called sotagliflozin, combined with a short ketogenic diet, can help suppress normal sugar use by the heart. This would make PET scans clearer for detecting inflammation caused by cardiac sarcoidosis. Forty healthy volunteers will take the drug for a week and follow a special diet for 1 or 3 days before a scan. The goal is to see if this approach improves image quality, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sotagliflozin (a drug that blocks sugar absorption to help the heart use less glucose)
What this could lead to: If successful, this could lead to a better, more reliable way to detect heart inflammation using PET scans, improving diagnosis of cardiac sarcoidosis.
What could go wrong: This is a very early pilot study in only 40 healthy people, not patients. It tests imaging, not treatment, so it may not translate to real-world diagnostic improvements.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC SARCOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiac sarcoidosis sarcoidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC SARCOIDOSIS

Contacts and locations

Locations

University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.